Navigation Links
OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
Date:7/20/2009

BOTHELL, WA and VANCOUVER, July 20 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today it has entered into purchase agreements with certain institutional investors for the sale of 475,000 shares of its common stock at a price of $20 per share through a registered direct offering. The transaction is expected to provide gross proceeds of $9.5 million to OncoGenex before deducting costs associated with the offering, and will be used primarily for manufacturing activities and general corporate purposes. The parties expect to close the transaction on or about July 24, 2009.

The shares of common stock offered by OncoGenex in this transaction will be issued pursuant to the Company's existing shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission on July 17, 2009. There was no placement agent in this transaction.

"These funds strengthen our balance sheet, substantially extending our runway and assisting our advancement toward our primary objective to secure a co-development and commercialization partner for our OGX-011 program," said Scott Cormack, President and CEO of OncoGenex. "It also allows us to continue our planned manufacturing readiness activities to ensure that our phase 3 trials initiate as planned once a partnership for OGX-011 is secured."

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or jurisdiction.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies t
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Pharmaceuticals Added to Russell Indexes
2. OncoGenex Pharmaceuticals Files Shelf Registration Statement
3. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
4. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
5. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
6. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
7. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
8. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
9. OncoGenex Reports First Quarter Financial Results
10. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
11. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies ... technologies, today announced that their third Phase ... reduction of recurrence of hypertrophic scars following ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:7/30/2014)... 2014 Vala Sciences was recently ... Protection Agency (EPA). This new contract was awarded ... including tests designed to assess the effect of ... of connections between neurons (synapses), which are critical ... formation by environmental pollutants likely contributes to a ...
(Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing novel ... of seed financing from friends and family investors. Proceeds ... a novel sustained-release product for ophthalmology. , "We are ... commitment to this important work," said Dr. Ken Mandell, ... many areas in which innovations in drug delivery have ...
(Date:7/29/2014)... have hurdled a number of significant technological challenges ... observing technology originally created for the James Webb ... Investigator Harvey Moseley, a scientist at NASA,s Goddard ... that electrostatically actuated microshutter arrays that is, ... are as functional as the current technology,s magnetically ...
Breaking Biology Technology:RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4
... (OTCQB: AHRO) ("AtheroNova"), a biotech company focused on the research ... that it has appointed Johan M. (Thijs) Spoor as a ... effective January 3, 2012. Mr. Spoor is an independent director ... the Board. "I am very pleased to ...
... Inc., has initiated its transition from technology development ... Stan Rose, Ph.D., as the company,s first chief ... Sklar, M.D., Ph.D., has agreed to join the ... pioneering the development of a novel technology with ...
... Jan. 5, 2012  ZyGEM Corp. Ltd., a developer ... of DNA and other nucleic acids, and the ... (USAMRIID), today announced the signing of a Cooperative ... of simplified sample processing solutions for biothreat agents. ...
Cached Biology Technology:AtheroNova Announces a New Board Member 2AtheroNova Announces a New Board Member 3Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology 2Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology 3Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology 4ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 2ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 3
(Date:7/29/2014)... Achalasia is a rare disease it affects 1 in ... in the esophageal wall. While its cause remains unknown, a ... in Belgium, the University of Bonn in Germany and other ... autoimmune in origin. The study, published on 6 July in ... the mysterious disease. , When we swallow, a sphincter in ...
(Date:7/28/2014)... the U.S. Food and Drug Administration (FDA) for other ... pathogens inside human cells, including those that cause Legionnaires, ... in mBio , the online open-access journal of ... of identifying non-antibiotic drugs that could one day help ... on the list inhibit the growth of at least ...
(Date:7/28/2014)... researchers led by the University of Arizona has sequenced ... information will enhance scientists, and agriculturalists, understanding of the ... the development of new rice varieties that are better ... solve global hunger challenges. , The paper, "The genome ... evidence for independent domestication," was published online in ...
Breaking Biology News(10 mins):Mysterious esophagus disease is autoimmune after all 2New route to identify drugs that can fight bacterial infections 2Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4
... Cowman has won the Mahathir Science Award in Tropical ... the Academy of Sciences Malaysia, in recognition of his ... Foundation chairman Tun Ahmad Sarji Abdul Hamid made the ... to the global malaria research effort, leading studies into ...
... November 7, 2013 The knowledge and skills required to ... unavailable to those living with financial limitations. Competing demands ... achieving better diets. However, two researchers at the ... at the effects that three educational sessions might have ...
... associated with hydrocarbon extraction can negatively affect aquatic ... in the open-access journal PLOS ONE ... and other institutions. Hydrocarbons are a primary ... exploration and extraction are profitable enterprises, hydrocarbons contribute ...
Cached Biology News:Professor Alan Cowman wins Malaysian science award 23 'hands on' nutrition classes -- Enough to impact health behaviors in lower income women 2Drilling for hydrocarbons can impact aquatic life 2
... smallest electronic pressure controller available measuring 26 ... this unit specifically for the analytical instrumentation ... carrier gas flow control, microfluidic flow control, ... focusing, the OEM-EPC offers external pressure sensor ...
... Stroke Thrust Slide is designed for heavy ... are limited and substantial side-loading is present. ... provide millions of trouble-free cycles even in ... bushings or recirculating ball bearings , Optional ...
... offered in several versions. The Captiva 0.2 ... are ideal to prepare precipitated protein samples ... and necessary to prevent clogging of expensive ... fiber and 20 um polypropylene filter plates ...
... CyScribe Post-Labeling Kit with CyScribe GFX ... generation and purification of Cy3- and ... for complete cDNA labeling and purification.Flexible ... for performing labeling reactions with either ...
Biology Products: